Michael Dunne

Track

Insider profile

Currently holds a position at Iterum Therapeutics PLC

Performance

Overall performance
2.7
Performance over holding periods
2.7
30 days 90 days 120 days
Average return -3% 8.2% 15.1%
Success rate 30% 68% 82%
Transactions
7 86% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Chief Scientific Officer Iterum Therapeutics PLC Nov. 1, 2015 -
Michael Dunne's trades of Iterum Therapeutics PLC's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Purchase
Price
230.72
Quantity 80,647 +17.6%
Value US$4,110,547
Transaction date
Purchase
Price
143.50
Quantity 67,223 -47.3%
Value US$1,755,500
Transaction date
Purchase
Price
162.37
Quantity 96,525 -36.5%
Value US$3,381,128
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-11-20 2025-11-18
B Purchase
80,647 +17.6%
230.72
US$4,110,547 		80,647 +17.6% 230.72 US$4,110,547
2025-08-12 2025-08-08
B Purchase
67,223 -47.3%
143.50
US$1,755,500 		67,223 -47.3% 143.50 US$1,755,500
2023-12-27 2023-12-22
B Purchase
96,525 -36.5%
162.37
US$3,381,128 		96,525 -36.5% 162.37 US$3,381,128
2023-12-19 2023-12-18
B Purchase
10,000 +12.7%
1.84
US$18,442 		10,000 +12.7% 1.84 US$18,442
2023-11-27 2023-11-22
B Purchase
20,000 +34.0%
2.03
US$40,690 		20,000 +34.0% 2.03 US$40,690
2022-09-09 2022-09-07
B Purchase
10,000 +39.1%
2.22
US$22,200 		10,000 +39.1% 2.22 US$22,200
2021-01-27 2021-01-26
S Sale
33,143 -11.4%
1.73
US$57,337 		33,143 -11.4% 1.73 US$57,337
2020-10-28 2020-10-27
B Purchase
61,540
0.00
US$0 		61,540 0.00 US$0